01/25/23 8:00 AMOTC : NBIO clinical trialNascent Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, announced the completion of the dosing period ofRHEA-AIneutral
01/10/23 8:00 AMOTC : NBIO Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer TrialNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion andRHEA-AIneutral
12/20/22 8:00 AMOTC : NBIO managementNascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory BoardNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting the treatment of various cancers, announced today that Dr. Ivan Babic, a renownedRHEA-AIneutral
11/01/22 8:00 AMOTC : NBIO Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company who develops monoclonal antibodies targeting treatment of various cancers, announced today that the United States Patent andRHEA-AIneutral
10/04/22 8:00 AMOTC : NBIO clinical trialNascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical ResearchNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company focused on the development of monoclonal antibodies targeting various cancer types, announced today that the Company hasRHEA-AIneutral
09/13/22 8:00 AMOTC : NBIO clinical trialNascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion of theRHEA-AIneutral
07/19/22 8:00 AMOTC : NBIO Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional PatentNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased toRHEA-AIneutral
06/07/22 8:00 AMOTC : NBIO clinical trialNascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain CancerNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased toRHEA-AIneutral
05/04/22 8:00 AMOTC : NBIO Nascent Biotech's CEO Sean Carrick Featured in In-Depth Interview with Proactive InvestorsNascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers, is pleased to announce that its CEO,RHEA-AIvery positive
04/12/22 8:00 AMOTC : NBIO Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal AntibodyNascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody showing promise in the treatment of brain cancer, has partnered with BioTools, Inc to clearly define PTB's higher order molecular structure (HOS). Nascent is exploring the potentialRHEA-AIneutral